Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 1148-1151

  Sevillano, David ^a   Calvo, Almudena ^a   Giménez, María José ^a   Alou, Luis ^a   Aguilar, Lorenzo ^a   Valero, Eva ^a   Carcas, Antonio ^b   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

lactams; Inocula decrease; Pneumococcal isolates

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SIMULATION; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; SUSTAINED RELEASE FORMULATION;

AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PENICILLIN RESISTANCE; STREPTOCOCCUS PNEUMONIAE;

EID: 12344323596     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh463     Document Type: Article

References (10)

1. Kaye, C. M., Allen, A., Perry, S. et al. (2001). The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clinical Therapeutics 23 578-84.
2. Doern, G. V. (2001). Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clinical Infectious Diseases 33, Suppl. 3 S187-92.
3. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity for Antimicrobial Agents. Tentative Guideline M26-T. NCCLS, Villanova, PA, USA.
4. Blaser, J., Stone, B. B. & Zinner, S. H. (1985). Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrobial Agents and Chemotherapy 27, 343-9.
5. Blaser, J., Stone, B. B., Groner, M. C. et al. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and the emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-60.
6. Balcabao, I. P., Aguilar, L., Martin, M. et al. (1996). Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Antimicrobial Agents and Chemotherapy 40, 2904-6.
7. Löwdin, E., Cars, O. & Odenholt, I. (2002). Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clinical Microbiology and Infection 8, 646-53.
8. Garau, J., Twynholm, M., García-Mendez, E. et al. (2003). Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. Journal of Antimicrobial Chemotherapy 52, 826-36.
9. Mueller, M., De la Peña, A. & Derendorf, H. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrobial Agents and Chemotherapy 48, 369-77.
10. Azoulay-Dupuis, E., Moine, P., Bedos, J. P. et al. (1996). Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrobial Agents and Chemotherapy 40, 941-6.